INTRODUCTION

Diabetes is a complex metabolic disorder characterized by high glucose levels in the blood (hyperglycaemia) due to insufficient insulin secretion and/or resistance to insulin’s action. Diabetes begets disease within different organs, including the eyes, kidneys, heart and blood vessels. These vascular complications are one of the main factors behind the significant morbidity (mainly microvascular complications, e.g. neuropathy, nephropathy and retinopathy) and mortality (mainly macrovascular complications, e.g. coronary heart disease and stroke) associated with the disease. The approach to managing macrovascular and microvascular complications formerly focused heavily on glycaemic control but greater emphasis over the years has been placed on blood pressure, lipids and more recently better weight management, as well as use of novel diabetes agents which lower vascular risks.

Even though most published statements and guidelines encourage tight glycaemic control as a way of lowering the risk of micro- and macrovascular complications, the results from trials have shown modest benefits. For example,
a recent meta-analysis of intensive glucose lowering trials reported a reduction in the risk of kidney events by 20% and by 13% for eye events, but the risk was not reduced for nerve events. An earlier meta-analysis of the same trials identified intensive glycaemic control resulted in 17% reduction in risk of non-fatal myocardial infarction and 15% reduction in risk of coronary heart disease but had no significant effect on events of stroke or all-cause mortality. While it must be remembered these trials were relatively short term, these modest findings raise the question of what factors other than hyperglycaemia per se contribute to developing those complications among people with diabetes. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have been shown to lower cardiovascular and cardiorenal outcomes in people with type 2 diabetes by levels that cannot be explained by reduction in glucose per se.

In this review, we focus on type 2 diabetes as the dominant type of the disease which accounts for 90% of all types. We appraise the evidence gained from studies employing a Mendelian randomization strategy (Figure 1) to answer whether type 2 diabetes is causally associated with microvascular and macrovascular complications, and if so, which component(s) of type 2 diabetes drives this risk.

2 DIABETES COMPLICATIONS

Microvascular complications refer to those long-term complications that affect small blood vessels. Diabetic retinopathy is the most common diabetes-associated microvascular complication and the leading cause of visual loss among people with diabetes. Several studies have investigated the pathophysiological role of hyperglycaemia in developing diabetic retinopathy. However, a clear mechanism is yet to be established. Diabetic nephropathy (either persistent albuminuria or evidence of low eGFR, or often both) develops in 40% of people with all types of diabetes and is the leading cause of chronic kidney disease (eGFR below the threshold of 60 ml/min per 1.73 m²) among those affected with diabetes worldwide. The aetiology of diabetic nephropathy is not clearly understood. Diabetic neuropathy includes a large spectrum of neuropathic syndromes, including sensory, motor and autonomic peripheral neuropathy. Diabetic polyneuropathy is the most common type of diabetes-associated neuropathies and affects around 50% of people with different types of diabetes.

FIGURE 1 The analogy between Mendelian randomization and Randomized Controlled Trials (RCT). In an RCT, participants are randomly assigned to either treatment or control group and receive a different treatment or management protocol. Consequently, reverse causation and bias are significantly reduced as randomization and group assignment is done at the start of the study. In Mendelian randomization, participants are grouped according to their genetic risk profile for the exposure of interest. For example, to investigate whether type 2 diabetes is causally associated with vascular complications, individuals are randomized based on their genetically defined type 2 diabetes liability. The random inheritance of genetic variants from each parent independent of the outcome, environment and lifestyle factors, reduces the chance of reverse causation and confounding factors.
Macrovacular complications refer to damage in the body's large blood vessels. Previous studies have found two- to three-fold increased risk of coronary heart disease among those with type 2 diabetes. Insulin resistance and obesity play a role in developing coronary heart disease. However, a clear causal association is yet to be established, with recent studies proposing an effect of other factors such as low socio-economic status that could partially mediate the link between insulin resistance, obesity and cardiovascular diseases. Stroke is a major cerebrovascular complication that is associated with type 2 diabetes. People diagnosed with type 2 diabetes are highly susceptible to a cerebral small vessel disease. The INTERSTROKE study, which was conducted across 22 countries, reported a 35% higher risk for stroke among those with a previous history of diabetes.

3 | LIMITATIONS OF OBSERVATIONAL STUDIES IN ESTABLISHING A CAUSAL LINK BETWEEN TYPE 2 DIABETES AND MICRO/MACROVASCULAR COMPLICATIONS

Observational studies have already established a clear link between type 2 diabetes and various micro- and macrovascular complications. However, determining whether there is a causal relationship between type 2 diabetes and vascular complications has been challenging. Lack of randomization, susceptibility to bias (e.g. measurement error, small sample size), the existence of confounding factors (e.g. obesity may independently influence both the risk of type 2 diabetes and vascular complications) and reverse causation (e.g. the development of vascular disease could precede and accelerate the development of type 2 diabetes) make observational studies often less capable of establishing a causal link between type 2 diabetes (or its components) and its associated vascular complications.

Randomized controlled trials (RCTs) remain the gold standard for establishing a causal association. However, they are often difficult to perform, costly and methodologically difficult to address the question of which aspects of type 2 diabetes causes vascular complications, as few interventions influence only one risk factor. Furthermore, many treatments for hyperglycaemia influence multiple pathways so it is near impossible to dissect out what aspect of a drug therapy lowers risk. This is particularly true for the newer SGLT2i and GLP-1RAs. Application of a genetic analogue, called Mendelian randomization, for the RCT (Figure 1) can help overcome many shortcomings of observational studies in a safe, reliable and, often inexpensive manner. This method is for investigating the existence of a causal relationship between environmental, lifestyle or disease exposures (e.g. type 2 diabetes) and an outcome (e.g. vascular complications).

4 | THE PRINCIPLES OF MENDELIAN RANDOMIZATION

Mendelian randomization is a statistical method that uses genetic variants (instrumental variables) as proxies for environmental and lifestyle exposure to find evidence of causal inference between a potentially modifiable risk factor and a disease. The method is based on Mendel's law of independent assortment, where genes are inherited randomly from parents to offspring. Valid instrumental variables are fundamental for the success of a Mendelian randomization study. The instrument's validity is satisfied by three assumptions that must be evaluated before using the genetic instrument (Figure 2). First, the relevance assumption implies that instrumental variables must be associated with the exposure of interest. Second, the independence assumption states that there has to be no shared common cause between the instrumental variants and confounding factors. Third, the exclusion restriction assumption implies that the instrument variables do not affect the outcome except through the risk of interest.

As shown in Figure 1, Mendelian randomization is designed similarly to RCTs. In an RCT, participants are randomly assigned to either treatment or control group and receive a different treatment or management protocol. Consequently, reverse causation and bias are eliminated as randomization is done before the study. In Mendelian randomization, participants are grouped according to their genetic risk profile for the exposure of interest. The random inheritance of genetic variants from each parent independent of the outcome, environment and lifestyle factors, reduces the chance of reverse causation and confounding factors. Using statistical analysis based on genetic variants as an instrument, in a Mendelian randomization design, eliminates the interference of known and unknown confounders and the possibility of reverse causality because genes are inherited randomly and remain nonmodifiable during the course of life.

Although Mendelian randomization is the best alternative for RCT in estimating causal relationships, some caution is needed in interpreting the results when applying this method. First, the major issue is a phenomenon known as ‘pleiotropy’ where the genetic instrument is associated with other traits (potential exposures or confounders) (Figure 3). Second, the weak instrument can bias the findings towards false negative causal association. Therefore, it is important to use a genetic instrument that is robustly and strongly associated...
with the exposure of interest. Third, since the discovery of majority of genetic instruments is performed in Europeans only, the generalizability of Mendelian randomization results to other ethnic groups is limited. Fourth, Mendelian randomization estimates the effect of a risk factor over a lifetime and cannot estimate the effect of an intervention at a specific age.

5 | EVIDENCE FROM MENDELIAN RANDOMIZATION STUDIES FOR A CAUSAL ASSOCIATION BETWEEN TYPE 2 DIABETES AND MICRO/MACROVASCULAR COMPLICATIONS

Several Mendelian randomization studies have been conducted to identify a causal association between type 2 diabetes and its associated macro- and microvascular complications. These studies suggest that genetically predicted higher risk of type 2 diabetes is associated with higher risk of coronary atherosclerosis, ischaemic heart disease, ischaemic stroke, myocardial infarction, peripheral artery disease, aortic valve stenosis and heart failure using data from mainly European ancestries \(^\text{26-28}\) (Figure 4). The genetic evidence does not support a causal role of type 2 diabetes on risk of atrial fibrillation or intracerebral haemorrhage.\(^\text{28,29}\)

6 | WHAT ASPECT OF TYPE 2 DIABETES IS DRIVING THE RISK?

Type 2 diabetes is a collection of different metabolic features and events which make it a complex heterogeneous disease in terms of clinical presentation, disease course, response to treatment and complication risk. These metabolic features include β-cell dysfunction,
insulin resistance, lipodystrophy (in small number of cases), excess adiposity and lipid pathways. The contribution of the metabolic derangements to the development of type 2 diabetes can be markedly different among affected individuals. Evidence offered by genetic studies has introduced the concept of subtypes of type 2 diabetes although this area remains highly controversial and contested. 

Any association between type 2 diabetes and vascular complications could be driven by a particular metabolic trait or pathways. With personalized and precision medicine in type 2 diabetes rapidly evolving, understanding which type 2 diabetes components are mostly associated with the risk of micro- and macrovascular complications could provide an opportunity for individualized treatment and management plan. This insight will allow clinicians to predict the risk of specific vascular complications based on the associated diabetes component and provide a management plan consequently. For example, if excess adiposity is causally associated with risk of diabetic kidney disease, people with type 2 diabetes with higher BMI levels should receive medications that lower weight more for potentially greater protection. This remains speculative and trials are needed to provide more evidence.

In the following section, we discuss how hyperglycaemia, insulin resistance, obesity and hypertension could influence risk of vascular complications using evidence from Mendelian randomization studies (Table 1).

### 6.1 Hyperglycaemia

Both observational and genetic studies have investigated the role of hyperglycaemia in developing diabetes-associated micro- and macrovascular complications. However, the mechanism by which the risk for those complications is driven remains vague, notably in diabetic peripheral neuropathy. Mendelian randomization using genetic variants associated with hyperglycaemia started in 2015. Studies investigated the impact of hyperglycaemia from the prediabetes stage to understand the glycaemic association with vascular complications. In this context, 47 genetic variants from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) associated with fasting blood glucose in nondiabetic range were used to investigate the causal inference of prediabetes on coronary artery disease, stroke and chronic kidney disease. The results of this study suggested that 1 mmol/L higher fasting blood glucose in individuals without diabetes increased the risk of coronary artery disease by an odds ratio of 1.26 (95% confidence interval [CI]: 1.16, 1.38) and concluded that high fasting glucose in prediabetes is only causally associated with coronary artery disease but not stroke or chronic kidney disease. Another study investigated the causal inference of higher HbA1c on the increased risk for cardiovascular diseases, namely haemorrhagic stroke, peripheral vascular disease and pulmonary embolism and found genetically predicted higher HbA1c
Summary of Mendelian randomization studies examining whether type 2 diabetes or its associated components are causally associated with higher risk of micro- and macrovascular diseases. The table include the following columns

| Exposure | Study | Complication | OR    | LCI   | UCI   | n.Case | n.Contr | Cohort                          |
|----------|-------|--------------|-------|-------|-------|--------|---------|---------------------------------|
| BMI      | Chatterjee et al. (2017) | Atrial fibrillation | 1.11  | 1.05  | 1.18  | 4178   | 51,646  | AGES/ARIC/FHS/PREVEND/WGHS |
| BMI      | Larsson et al. (2020) | Abdominal aortic aneurysm | 1.06  | 0.96  | 1.16  | 758    | 3,66,945 | UKBB               |
| BMI      | van’t Hof et al. (2017) | Abdominal aortic aneurysm | 1.63  | 0.99  | 2.61  | 818    | 3004   | Dutch population          |
| BMI      | Larsson et al. (2020) | Coronary artery disease | 1.07  | 1.04  | 1.09  | 24,531 | 3,43,172 | UKBB               |
| BMI      | Larsson et al. (2020) | Ischaemic stroke | 1.03  | 0.99  | 1.07  | 3554   | 3,64,149 | UKBB               |
| BMI      | Larsson et al. (2020) | Peripheral artery disease | 1.66  | 1.56  | 1.76  | 3514   | 3,64,189 | UKBB               |
| BMI      | Todd et al. (2015) | Diabetic kidney disease | 1.33  | 1.17  | 1.51  | 2916   | 3315   | UK-ROI/FinnDiane/GoKinD US  |
| BMI      | Todd et al. (2015) | End-stage renal disease | 1.43  | 1.2   | 1.72  | 2916   | 3315   | UK-ROI/FinnDiane/GoKinD US  |
| BMI      | Todd et al. (2015) | Macroalbuminuria | 1.28  | 1.11  | 1.45  | 2916   | 3315   | UK-ROI/FinnDiane/GoKinD US  |
| BMI      | Zheng et al. (2021) | Chronic kidney disease | 1.78  | 1.64  | 1.94  | 51,672 | 9,58,102 | CKDGen, UK Biobank and HUNT |
| BMI      | Huang et al. (2016) | Peripheral artery disease | 1.44  | 1.18  | 1.75  | 707    | 10,776 | Chinese population from Shanghai |
| BMI      | Martin et al. (2022) | Coronary artery disease | 1.41  | 1.1   | 1.81  | 43,054 | 4,07,969 | CIHDS/CCHS/CGPS/ Cardiogram |
| BMI      | Martin et al. (2022) | Stroke | 1.19  | 1.07  | 1.31  | 14,171 | 1,33,027 | Finngen/Published GWAS |
| BMI      | Martin et al. (2022) | Peripheral artery disease | 1.87  | 1.46  | 2.39  | 5323   | 1,67,843 | Chinese population          |
| BMI      | Martin et al. (2022) | Atrial fibrillation | 1.65  | 1.33  | 2.05  | 17,325 | 97,214 | Finngen/Published GWAS     |
| BMI      | Shah et al. (2020) | Heart failure | 1.61  | 1.45  | 1.79  | 47,309 | 9,30,014 | HERMES, UK Biobank     |
| BMI      | Martin et al. (2022) | Heart failure | 1.86  | 1.6   | 2.16  | 9576   | 1,59,286 | Finngen/Published GWAS     |
| BMI      | Martin et al. (2022) | Chronic kidney disease | 1.21  | 1.08  | 1.36  | 2821   | 1,72,745 | Finngen               |
| BMI      | Martin et al. (2022) | Abdominal aortic aneurysm | 1.16  | 0.83  | 1.62  | 1919   | 1,67,843 | Finngen/Published GWAS |
| DBP      | Wan et al. (2021) | Cardiovascular disease | 1.05  | 0.96  | 1.16  | 45,746 | 50,216 | UKBB, European British population |
| DBP      | Wan et al. (2021) | Ischaemic heart disease | 1.04  | 0.93  | 1.16  | 36,748 | 50,216 | UKBB, European British population |
| DBP      | Wan et al. (2021) | Myocardial infarction | 1.09  | 0.96  | 1.24  | 27,500 | 50,216 | UKBB, European British population |
| DBP      | Wan et al. (2021) | Stable angina | 1.16  | 0.98  | 1.28  | 21,119 | 50,216 | UKBB, European British population |
| DBP      | Wan et al. (2021) | Unstable angina | 1.12  | 0.66  | 1.02  | 6190   | 50,216 | UKBB, European British population |
| DBP      | Wan et al. (2021) | Stroke | 0.82  | 0.71  | 0.96  | 10,785 | 50,216 | UKBB, European British population |
| $p$ value | Unit | Disease definition | Pleiotropy | n.SNPs |
|-----------|------|--------------------|------------|--------|
| <0.001   | 1-SID increase in BMI | Cases: AF diagnosed on ECG, Holter, or obtained from clinicians records, Controls: healthy | Final result after adjusting for pleiotropic SNPs | NA |
| 0.25     | 1-kg/m$^2$ increase in BMI | Cases: aortic aneurysm, controls: Healthy | Final result consistent with sensitivity analysis | 96 |
| <0.002   | 1-SID increase in BMI | Cases: ruptured/non-ruptured intracranial and abdominal Aortic aneurysm, controls: healthy | Final result consistent with sensitivity analysis | 97 |
| 1.30E-05 | 1-kg/m$^2$ increase in BMI | Cases versus healthy controls | Final result consistent with sensitivity analysis | 404 |
| <0.001   | 1-kg/m$^2$ higher BMI | Cases: ischaemic stroke, controls: HeBurgesshty | Final result consistent with sensitivity analysis | 96 |
| 1.40E-03 | 1-kg/m$^2$ increase in BMI | Cases: peripheral artery disease, controls: HeBurgesshty | Final result consistent with sensitivity analysis | 96 |
| 0.62     | 1-kg/m$^2$ higher BMI | Cases: T1D with ACR >300 and ESRD, cases with ESRD, cases. Controls: T1D | Final result after adjusting for pleiotropic SNPs | 32 |
| <0.001   | 1-kg/m$^2$ higher BMI | T1D with Macroalbumininuria cases versus T1D without ESRD, controls T1D | Final result after adjusting for pleiotropic SNPs | 32 |
| 0.001    | 1-kg/m$^2$ higher BMI | Cases: T1D with ACR >300, Controls: T1D | Final result after adjusting for pleiotropic SNPs | 32 |
| <0.001   | 1-SID increase in BMI | CKD cases versus controls | Final result consistent with sensitivity analysis | 902 |
| 0.0004   | 1-SID increase in BMI GRS | Cases: having ABI <0.9 or >1.4 at either side, controls: Healthy | Final result consistent with sensitivity analysis | 14 |
| 0.007    | 1-SID increase in BMI | cases: IHD/stenosis/atherosclerosis/positive ECG/ MI, controls: Healthy, controls: healthy | Final result consistent with sensitivity analysis | 73 |
| 1.00E-03 | 1-SID increase in BMI | Cases: stroke as per WHO definition, controls: Healthy | Final result consistent with sensitivity analysis | 73 |
| 4.00E-06 | 1-SID increase in BMI | 11,837 Chinese participants from Shanghai | Final result consistent with sensitivity analysis | 73 |
| 5.00E-06 | 1-SID increase in BMI | Cases: Paroxysmal or permanent atrial fibrillation, or atrial flutter, controls: Healthy | Final result consistent with sensitivity analysis | 73 |
| 2.70E-50 | 1-SID increase in BMI | Cases: Heart failure, controls: Healthy | Final result consistent with sensitivity analysis | 89 |
| 2.00E-16 | 1-SID increase in BMI | Cases: any aetiology of heart failure with no inclusion criteria based on left ventricular ejection fraction, Controls: Healthy | Final result consistent with sensitivity analysis | 73 |
| 0.002    | 1-SID increase in BMI | Cases: eGFR<60?ml?min–1?per 1.73?m2, controls: Healthy | Final result consistent with sensitivity analysis | 73 |
| 0.394    | 1-SID increase in BMI | Cases: an infrarenal aortic diameter greater than 30mm excluding secondary aneurysm, Controls: Healthy | Final result consistent with sensitivity analysis | 73 |
| 0.6      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.7      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.4      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.4      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.4      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.2      | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| Exposure      | Study                              | Complication                        | OR  | LCI   | UCI   | n.Case | n.Contr | Cohort                                      |
|--------------|-----------------------------------|-------------------------------------|-----|-------|-------|--------|---------|---------------------------------------------|
| DBP          | Wan et al. (2021)                 | Ischaemic stroke                    | 0.9 | 0.76  | 1.06  | 9165   | 50,216  | UKBB, European British population           |
| DBP          | Wan et al. (2021)                 | Intracerebral haemorrhage           | 0.64| 0.41  | 1     | 1154   | 50,216  | UKBB, European British population           |
| DBP          | Wan et al. (2021)                 | Heart failure                       | 0.93| 0.78  | 1.11  | 7650   | 50,216  | UKBB, European British population           |
| DBP          | Wan et al. (2021)                 | Peripheral vascular disease         | 0.83| 0.69  | 1     | 8131   | 50,216  | UKBB, European British population           |
| DBP          | Wan et al. (2021)                 | Arrhythmia                          | 0.9 | 0.75  | 1.09  | 24,637 | 50,216  | UKBB, European British population           |
| Fasting glucose | Ahmad et al. (2015)              | Coronary Heart disease              | 1.15| 1     | 1.32  | 63,746 | 1,30,681| Cardiogramplus                              |
| Fasting glucose | Harati et al. (2019)            | Atrial fibrillation                 | 0.95| 0.82  | 1.09  | 60,620 | 9,70,210| HUNT/DECODE/MGI/DiscovEHR/AFGen             |
| Fasting glucose | Kim et al. (2020)               | Chronic kidney disease              | 0.99| 0.98  | 1     | 5909   | 10,030 | Korean population/KoGES/KARE               |
| Fasting glucose | Merino et al. (2017)          | Coronary artery disease             | 1.43| 1.14  | 1.79  | 63,746 | 1,30,681| UKBB                                        |
| Fasting glucose | Ross et al. (2015)              | Coronary heart disease              | 1.18| 0.97  | 1.42  | 85,979 | 1,95,443| Cardiogramplus                              |
| Fasting Insulin | Larsson et al. (2017)          | Ischaemic stroke                    | 1.03| 0.78  | 1.37  | 37,296 | 18,476 | METASTROKE, NINDS-SIGN                      |
| Fasting Insulin | Liu et al. (2018)              | Lacunar stroke                      | 1.52| 0.45  | 5.08  | 2191   | 27,297 | NA                                          |
| Fasting Insulin | Tikkanen et al. (2016)         | Coronary heart disease              | 1.06| 1.02  | 1.1   | 5834   | 11,668 | FINRISK/DILGOM/Corogene/Genmets             |
| Fasting Insulin | Zhan et al. (2017)              | Coronary Heart disease              | 1.86| 1.01  | 3.41  | 22,233 | 64,762 | CARDioGRAMplusC4D/ENGAGE                   |
| HbA1c         | Harati et al. (2019)             | Atrial fibrillation                 | 1.01| 0.85  | 1.17  | 60,620 | 970,21 | HUNT/DECODE/MGI/DiscovEHR/AFGen            |
| HbA1c         | Leong et al. (2019)              | Coronary heart disease              | 1.61| 1.4   | 1.84  | 79,716 | 5,79,475| UKBB, Cardiogramplus                       |
| HbA1c         | Mutie et al. (2020)              | Coronary artery disease             | 1.03| 0.64  | 1.64  | 1,23,733| 4,24,528| UKBB, Cardiogramplus                       |
| HbA1c         | Ross et al. (2015)               | Coronary artery disease             | 1.53| 1.14  | 2.05  | 85,979 | 1,95,443| UKBB, Cardiogramplus                       |
| Insulin Resistance (IR) | Chen et al. (2020)          | Coronary artery disease             | 1.79| 1.57  | 2.04  | 60,801 | 1,23,504| GLGC, CARDIOGRAM/GENESIS                   |
| Insulin Resistance (IR) | Chen et al. (2020)          | Ischaemic stroke                    | 1.21| 1.05  | 1.4   | 67,162 | 4,54,450| GLGC, CARDIOGRAM/GENESIS                   |
| Insulin Resistance (IR) | Chen et al. (2020)          | Myocardial infarction               | 1.78| 1.54  | 2.06  | 60,801 | 1,23,504| GLGC, CARDIOGRAM/GENESIS                   |
| Insulin Resistance (IR) | Chen et al. (2020)          | Small-artery occlusion type stroke  | 1.8 | 1.3   | 2.49  | 67,162 | 4,54,450| GLGC, CARDIOGRAM/GENESIS                   |
| Insulin Resistance (IR) | Zhao et al. (2019)          | Atrial fibrillation                 | 3.23| 1.88  | 5.56  | 14,442 | 3,92,010| UKBB                                        |
| Non-fasting glucose | Benn et al. (2012)             | Ischaemic Heart disease             | 1.25| 1.03  | 1.52  | 14,155 | 66,367 | CIHDS/CCHS/CGPS                            |
| Non-fasting glucose | Benn et al. (2012)             | Myocardial infarction               | 1.69| 1.28  | 2.23  | 6257   | 74,265 | CIHDS/CCHS/CGPS                            |
| SBP           | Wan et al. (2021)               | Unstable angina                     | 1.69| 1.38  | 2.08  | 6190   | 50,216 | UKBB, European British population           |
| SBP           | Wan et al. (2021)               | Stroke                              | 1.72| 1.49  | 2     | 10,785 | 50,216 | UKBB, European British population           |
| SBP           | Wan et al. (2021)               | Ischaemic stroke                    | 1.55| 1.32  | 1.82  | 9165   | 50,216 | UKBB, European British population           |
| SBP           | Wan et al. (2021)               | Intracerebral haemorrhage           | 2.57| 1.66  | 3.97  | 1154   | 50,216 | UKBB, European British population           |
| p value | Unit | Disease definition | Pleiotropy | n.SNPs |
|---------|------|--------------------|------------|--------|
| 0.5     | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.3     | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.7     | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.3     | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.6     | 5 mm/Hg DBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 364 |
| 0.05    | 0.025 mmol/L per allele | Cases: non-diabetic participants with CHD, controls: Healthy | Final result after excluding pleiotropic SNPs | 24 |
| 0.49    | 1-SD increase/mmol | Cases: AF, controls: Healthy | Final result after excluding pleiotropic SNPs | 36 |
| 0.098   | 1-SD increase/mmol | General population | Final result after excluding pleiotropic SNPs | 9 |
| 0.02    | 1-mmol/L increase in FG | Cases: participants with CAD, controls: healthy | Final result after excluding pleiotropic SNPs | 11 |
| >0.05   | No causal effect | Cases: participants with CAD, controls: healthy | Final result after excluding pleiotropic SNPs | 30 |
| 0.82    | 1-SD increase for FI | Cases: ischaemic stroke, controls: Healthy | Final result consistent with sensitivity analysis | 18 |
| 0.288   | NA | Cases: intracerebral haemorrhage, controls: Healthy matched for age, sex, race | Final result after excluding pleiotropic SNPs | 9 |
| 0.5     | NA | Cases: lacunar stroke, controls: Healthy | Final result after excluding pleiotropic SNPs | 9 |
| 0.002   | 1-SD increase of GRS | Cases: MI, unstable angina/coronary revasc, death from CHD, controls: healthy | Final result after excluding pleiotropic SNPs | 20 |
| 0.04    | log-transformed fasting insulin | Cases: coronary heart disease, controls: Healthy | Final result after excluding pleiotropic SNPs | 10 |
| 0.88    | 1-SD mol (%) for HbA1c | Cases: AF, controls: Healthy | Final result after excluding pleiotropic SNPs | 11 |
| 1.00E-09| 1-SD increase in BMI | Cases: coronary heart disease, controls: Healthy | Final result suggests presence of pleiotropy | 36 |
| >0.05   | No causal effect | Cases: coronary artery disease, controls: Healthy | Final result consistent with sensitivity analysis | 10 |
| 0.002   | 1% increase in HbA1c | Cases: coronary artery disease, controls: Healthy | Final result after excluding pleiotropic SNPs | 9 |
| <0.001  | 1-SD increase in IR | Cases: ischaemic stroke/stroke subtypes, controls: Healthy | Final result consistent with sensitivity analysis | 52 |
| 0.007   | 1-SD increase in IR | Cases: ischaemic stroke/stroke subtypes, controls: Healthy | Final result consistent with sensitivity analysis | 52 |
| <0.001  | 1-SD increase in IR | Cases: ischaemic stroke/stroke subtypes, controls: Healthy | Final result consistent with sensitivity analysis | 52 |
| <0.001  | 1-SD increase in IR | Cases: ischaemic stroke/stroke subtypes, controls: Healthy | Final result consistent with sensitivity analysis | 52 |
| 0.004   | 1-SD increase in IR | Cases: atrial fibrillation, controls: Healthy | Final result after excluding pleiotropic SNPs | 7 |
| <0.001  | 1-mmol/L increase NFBG | Cases: IHD/stenosis/atherosclerosis/positive ECG/ MI, controls: Healthy | Final result consistent with sensitivity analysis | 5 |
| <0.001  | 1-mmol/L increase NFBG | Cases: IHD/stenosis/atherosclerosis/positive ECG/ MI, controls: Healthy | Final result consistent with sensitivity analysis | 5 |
| 0.01    | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 327 |
| 0.0003  | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 327 |
| 0.007   | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 327 |
| 0.03    | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy | Final result consistent with sensitivity analysis | 327 |

(Continues)
TABLE 1 (Continued)

| Exposure | Study | Complication                      | OR    | LCI   | UCI   | n.Case | n.Contr | Cohort                        |
|----------|-------|-----------------------------------|-------|-------|-------|--------|---------|-------------------------------|
| SBP      | Wan et al. (2021) | Heart failure                   | 1.42  | 1.2   | 1.69  | 7650   | 50,216  | UKBB, European British population |
| SBP      | Wan et al. (2021) | Peripheral vascular disease      | 1.39  | 1.16  | 1.66  | 8131   | 50,216  | UKBB, European British population |
| SBP      | Wan et al. (2021) | Arrhythmia                       | 1.32  | 1.18  | 1.7   | 24,637 | 50,216  | UKBB, European British population |
| Type 2 diabetes | Harati et al. (2019) | Atrial fibrillation             | 1.01  | 0.98  | 1.03  | 60,620 | 970,21  | HUNT/DECODE/MGI/DescovEHR/AF4 |
| Type 2 diabetes | Huang et al. (2022) | Coronary atherosclerosis        | 1.01  | 1     | 1.01  | 60,801 | 1,23,504 | UKBB                          |
| Type 2 diabetes | Huang et al. (2022) | Ischaemic Heart disease          | 1.13  | 1     | 1.15  | 60,801 | 1,23,504 | CARDIoGRAMplusC4D              |
| Type 2 diabetes | Huang et al. (2022) | Ischaemic stroke                 | 1.08  | 1.06  | 1.1   | 67,162 | 4,54,450 | MEGASTROKE                     |
| Type 2 diabetes | Huang et al. (2022) | Major coronary heart disease events | 1     | 1.002 | 1.004 | 60,801 | 1,23,504 | UKBB                          |
| Type 2 diabetes | Huang et al. (2022) | Myocardial infarction            | 1.13  | 1     | 1.16  | 60,801 | 1,23,504 | CARDIoGRAMplusC4D              |
| Type 2 diabetes | Huang et al. (2022) | Peripheral artery disease        | 1.21  | 1.16  | 1.25  | 60,801 | 1,23,504 | CARDIoGRAMplusC4D              |
| Type 2 diabetes | Huang et al. (2022) | Stroke                           | 1.08  | 1.07  | 1.11  | 67,162 | 4,54,450 | MEGASTROKE                     |
| Type 2 diabetes | Larsson et al. (2017) | Ischaemic stroke                 | 1.12  | 1.07  | 1.17  | 18,476 | 37,296  | MEGASTROKE/NINDS/SIGN           |
| Type 2 diabetes | Liu et al. (2018) | Intracerebral haemorrhage        | 1.07  | 0.89  | 1.28  | 2254   | 8195    | CDK portal/Cambridge ICH/UKBB  |
| Type 2 diabetes | Liu et al. (2018) | Lacunar stroke                   | 1.15  | 1.04  | 1.28  | 2191   | 27,297  | CDK portal/Cambridge ICH/UKBB  |
| Type 2 diabetes | Liu et al. (2018) | Aortic stenosis                  | 1.13  | 1.08  | 1.19  | 2244   | 3,67,703 | UKBB                          |
| Type 2 diabetes | Mordi et al. (2021) | Heart failure                    | 1.06  | 1.03  | 1.09  | 47,309 | 9,30,014 | HERMES, European population    |

Note: Exposure: The genetic instrument used for the respective Mendelian randomization study. Study: Author and year of publication. Complication: the outcome studied. OR (odds ratio), LCI (lower confidence interval) and UCI (upper confidence interval): change in the risk of outcome. n.Case (number of cases) and n.Contr (number of controls). Cohort: information about the ethnic group of each study. p value: the statistical significance of the exposure vs outcome association. Unit: for the effect size of each exposure. Disease definition: Definition of each outcome/complication. Pleiotropy: indicates either horizontal pleiotropy present, pleiotropic SNPs were removed, or no pleiotropy detected. n.SNPs: the number of SNPs identified to be associated with outcome in each study.

was associated with higher risk of coronary artery disease and stroke. 37

A recent comprehensive Mendelian randomization study was conducted by Emanuelsson et al 38 to investigate whether high non-fasting glucose levels in the normoglycaemic range (individuals with non-fasting glucose 2h after meal ≥4. to 11.0 mmol/L) and below the diabetes cut-off point (11.1 mmol/L) are causally associated with an increased risk of retinopathy, neuropathy, nephropathy, chronic kidney disease, peripheral arterial disease and myocardial infarction. They used genetic variants associated with high blood glucose among non-diabetic people (including GCP62/ABCB1 (rs560887), GCK (rs4607517), DGKB (rs2191349), ADCY5 (rs11708067), CDKN2A/B (rs10811661 and rs2383206) and TCF7L2 (rs7903146)) and found that 1 mmol/L higher non-fasting glucose in the normoglycaemic range is associated with higher risk of retinopathy (risk ratio 2.01 [95% CI 1.18–3.41]), peripheral neuropathy (2.15 [1.38–3.35]), diabetic nephropathy (1.58 [1.04–2.40]) and peripheral artery disease (1.19 [0.90–1.58]). While this is interesting, an important limitation of that study is the lack of fasting glucose or HbA1c data and therefore it is difficult to be certain of the validity of these findings generated on random glucose levels.
| p value | Unit                | Disease definition                                                                 | Pleiotropy                      | n.SNPs |
|---------|---------------------|-------------------------------------------------------------------------------------|---------------------------------|--------|
| 0.04    | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy                | Final result consistent with sensitivity analysis | 327    |
| 0.04    | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy                | Final result consistent with sensitivity analysis | 327    |
| 0.06    | 10 mm/Hg SBP increase | Cases: defined according to ICD-9 and ICD-10 codes, Controls: Healthy                | Final result consistent with sensitivity analysis | 327    |
| 0.37    | 1-SD increase/mmHg | Cases: AF, controls: Healthy                                                        | Final result after excluding pleiotropic SNPs | 122    |
| 0.008   | 1-SD increase mmol/mol | Cases: coronary atherosclerosis, controls: Healthy                                   | Final result consistent with sensitivity analysis | 277    |
| 0.001   | Genetically increased T2D | Cases: ischaemic heart disease, controls: Healthy                                | Final result consistent with sensitivity analysis | 269    |
| 0.01    | Genetically increased T2D | Cases: ischaemic stroke, controls: Healthy                                            | Final result consistent with sensitivity analysis | 269    |
| <0.001  | Genetically increased T2D | Cases: major coronary heart disease events, controls: Healthy                        | Final result consistent with sensitivity analysis | 231    |
| <0.001  | Genetically increased T2D | Cases: myocardial infarction, controls: Healthy                                        | Final result consistent with sensitivity analysis | 231    |
| <0.001  | Genetically increased T2D | Cases: peripheral artery disease, controls: Healthy                                  | Final result consistent with sensitivity analysis | 217    |
| <0.001  | Genetically increased T2D | Cases: stroke, controls: Healthy                                                     | Final result consistent with sensitivity analysis | 231    |
| 3.00E-06| 1-unit-higher log-odds for T2D | Cases: ischaemic stroke, controls: Healthy                                          | Final result consistent with sensitivity analysis | 49     |
| 0.269   | No causal effect | Cases: intracerebral haemorrhage, controls: Healthy                                  | Final result after excluding pleiotropic SNPs | 77     |
| 0.007   | Twofold increase in T2D | Cases: lacunar stroke, controls: Healthy                                             | Final result after excluding pleiotropic SNPs | 77     |
| <0.001  | Twofold increase in T2D | Cases: patients with aortic valve stenosis according to ICD9, ICD10, Controls: Healthy | Final result after excluding pleiotropic SNPs | 243    |
| <0.001  | 1-log unit higher odds of T2D | Cases: physician diagnosis of HF, image diagnosis, ICD codes, Controls: Healthy | Final result suggests presence of pleiotropy | 763    |

6.2 Insulin resistance

A study investigated the causal association between 53 genetic variants associated with insulin resistance (variants associated with elevated fasting insulin, lower HDL-C and higher triglyceride levels) reported a significant higher risk of coronary heart disease in general population after adjusting for fasting insulin and BMI (odds ratio 1.79, 95% CI: [1.57–2.04], p < 0.001), ischaemic stroke (1.21 [1.05–1.40], p = 0.007), small-artery occlusion subtype of stroke (1.80 [1.30–2.49], p < 0.001) and myocardial infarction (1.78 [1.54–2.06], p < 0.001) per 1-SD (standard deviation) increase in insulin resistance phenotype for all outcomes.\(^{39}\) Even though observational studies have linked insulin resistance to microvascular complications, the shortcomings of observational studies in terms of bias and reverse causation emphasize the need for further investigations to establish a causal association between insulin resistance and microvascular complications.

6.3 Body mass index

Body mass index (BMI), as a measure of obesity, has been the most studied risk factor. The association between obesity and macrovascular complications has been reported by observational studies.\(^{40,41}\) However, despite the similarity in etiology between macro- and microvascular complications, observational studies have been inconsistent in establishing an association between obesity and microvascular complications. Several relevant Mendelian randomization studies have been published. For instance, 1-SD increase in genetically estimated BMI was associated with a higher risk of diabetic nephropathy (odds ratio 3.76, 95% CI [1.88–7.53], p < 0.001) and reduced eGFR levels (estimated glomerular filtration rate) (0.71, [0.59–0.86], p < 0.001); however, no association was found between BMI and proteinuria.\(^{42}\) Another study on the causal effect of childhood BMI on the risk of adult type 2 diabetes, coronary artery disease and nephropathy using 15 genetic variants identified by the Early Growth Genetics
(EGG) consortium found that a 1-SD increase in childhood BMI was significantly associated with an increased risk of the adult onset of type 2 diabetes ranging from 47% to 83% (odds ratio 1.47 [1.18, 1.82] to 1.83 [1.46, 2.30]), 28% increased risk of adult coronary arteries disease (1.28 [1.17, 1.39]), but a borderline association was found with adult chronic kidney disease (1.14 [0.99, 1.31]). Another study used 97 genetic variants associated with BMI from the GIANT consortium (The Genetic Investigation of ANthropometric Traits) to assess the causal association between obesity and various human diseases. Contrary to the findings of some observational studies, which reported a lower risk of diabetic retinopathy to be associated with a higher BMI, this study found that genetically elevated BMI was an independent causal risk factor for diabetic retinopathy. This study once again suggests that results from observational studies which examine risks linked to BMI, may be misleading due to the unintentional loss of weight associated with long-standing diabetes.

7 | THE ROLE OF HYPERTENSION IN DIABETES-ASSOCIATED MICRO- AND MACROVASCULAR COMPLICATIONS

Diabetes and hypertension have several pathophysiological links due to common risk factors and complications. Macrovascular complications, for instance, are common findings in people with diabetes, hypertension or both. On the other hand, microvascular complications such as nephropathy, neuropathy and retinopathy are thought to be accelerated by hypertension.

Individuals diagnosed with type 2 diabetes are found to have a twofold risk of hypertension compared to healthy individuals, while those diagnosed with hypertension often exhibit insulin resistance and are at a higher risk of developing type 2 diabetes. Risk factors in the form of alcohol consumption, unhealthy lifestyle and obesity are behind the development of both conditions. The prevalence of coexistence of diabetes and hypertension ranges from 19% to 51% in Asian and Western countries. The UK Prospective Diabetes Study of systolic blood pressure among people with diabetes and any incident of microvascular or macrovascular complications reported a hazard ratio of 1.12 (p < 0.001) per 10 mmHg increments of systolic blood pressure. The study also found that individuals with HbA1c ≥64 mmol/mol and systolic blood pressure ≥150 mm Hg had a 16.3-fold higher risk of developing microvascular complications than those with HbA1c <42 mmol/mol and systolic blood pressure <130 mm Hg.

Type 2 diabetes has been found to be associated with a higher risk of hypertension and vice versa; however, the causality between both conditions remains uncertain. A bidirectional Mendelian randomization study was conducted on participants from the UK biobank study using genetic variants for type 2 diabetes and hypertension. The study found that type 2 diabetes is causally associated with higher risk of hypertension (odds ratio 1.07 [95% CI, 1.04–1.10], p = 3.4 × 10^{-7}), while no causal link was detected for hypertension causing type 2 diabetes (odds ratio 0.96 [0.88–1.04], p = 0.34). Moreover, type 2 diabetes was associated with 0.67 mm Hg higher systolic blood pressure (95% CI 0.41–0.93, p = 5.75 × 10^{-7}), but no association was seen with diastolic blood pressure.

Mendelian randomization studies to investigate the role of hypertension in risk of diabetes vascular complications are mainly limited to macrovascular conditions and have provided evidence for a causal role of hypertension in higher risk of cardiovascular disease, stroke, myocardial infarction, heart failure and peripheral vascular disease. A recent study used 327 and 364 genetic variants strongly and independently associated with systolic and diastolic blood pressure, respectively, found that 10 mm Hg increase in systolic blood pressure was associated with increased risk of total cardiovascular disease (odds ratio 1.32 [95% CI, 1.25–1.40]), ischaemic heart disease (1.33, [1.24–1.41]) and stroke (1.35, [1.24–1.48]), while 5 mm Hg increase in diastolic blood pressure was causally associated with total cardiovascular disease (1.20 [1.14–1.27]), ischaemic heart disease (1.20 [1.15–1.26]) and stroke (1.20 [1.12–1.28]).

8 | EVIDENCE FROM STUDIES OF NON-EUROPEANS

Mendelian randomization studies in non-European are scarce due to limited genome-wide association study (GWAS) data. Few studies investigated the causal effect of type 2 diabetes and its components on the risk of vascular complications. A Mendelian randomization study by Jie Zheng et al. investigated the causal effect of 45 cardiometabolic risk factors, including type 2 diabetes, on the risk of chronic kidney disease among European and three East Asian Biobanks. The study found that type 2 diabetes causally increased the risk of chronic kidney disease among all three populations (Europeans, Chinese and Japanese) consistently. BMI increased the risk of chronic kidney disease among Europeans and individuals from the Japanese Biobanks but not among the China Kadoorie individuals which could be due to either limited cases of chronic kidney disease in the China Kadoorie Biobank or ethnic-based difference. Systolic blood pressure had strong causal effect among Europeans but showed no evidence among East Asian population, which could indicate an ancestry-based role for systolic blood pressure in the development of chronic kidney disease. Another Mendelian randomization study by
Xuehao et al. found consistent causal effect of type 2 diabetes on higher risk of peripheral artery disease among both European and East Asian individuals. Such evidence could suggest that type 2 diabetes is less likely to be affected by ethnic variation in the development of vascular complications, however, multiple studies among different ethnic groups are needed for better judgement and understanding.

9 | CONCLUSION AND FUTURE WORK

Based on the available evidence from both observational and genetic studies, there appears a causal role played by type 2 diabetes in the development of cardiovascular disease, coronary heart disease, stroke, retinopathy and nephropathy but less clear in diabetic neuropathy and other macrovascular complications such as intracerebral haemorrhage and peripheral artery disease.

Given that type 2 diabetes is a disease of ectopic fat mass (including in liver and circulation as higher triglycerides), and that high BMI is one of its main risk factors, it is notable that higher BMI appear causal for not only cardiovascular complication, but also diabetic nephropathy, low eGFR as well as retinopathy. Type 2 diabetes and higher BMI also appear causal for hypertension, and it is important to note hyperglycaemia is also related to cardiovascular complications. Clearly, much more genetic work needs to be done to tease out to what extent each of the type 2 diabetes risk factors (or its underlying pathways) are relevant for differing complications but the data to date, as summarized, suggest an important role for excess weight in range of type 2 diabetes complications. This is interesting, as there appears to be an increasing focus on treating excess weight in the management of type 2 diabetes, both for remission and potentially reduction in multiple complications. This focus on a need to target excess weight more in type 2 diabetes has also been recognized in the recently updated ADA/EASD recommendations. The work summarized also provide more evidence for a multifactorial approach (targeting not only glycaemia but also blood pressure, excess weight and lipids) to treating type 2 diabetes to prevent complications. Further developments in genetic analyses should help tease out relative contributions of each diabetes component on its various complications, findings which could translate to better defined intervention trials and, eventually, to clinical guidelines.

ACKNOWLEDGEMENTS

We acknowledge all researchers who have contributed to this field and apologize to scientists whose work could not be highlighted due to space and reference limitations. HY acknowledges support by grant from a Diabetes UK RD Lawrence fellowship (17/0005594).

CONFLICT OF INTEREST

NS has received grant and personal fees from AstraZeneca, Boehringer Ingelheim and Novartis; grant from Roche Diagnostics; and personal fees from Abbott Laboratories, Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi outside the submitted work.

DATA AVAILABILITY STATEMENT

I confirm that my Data Availability Statement (pasted below) complies with the Expects Data Policy. The data that support the findings of this study are available in the supplementary material of this article.

ORCID

Naveed Sattar https://orcid.org/0000-0002-1604-2593
Hanieh Yaghootkar https://orcid.org/0000-0001-9672-9477

REFERENCES

1. Petersmann A, Möller-Wieland D, Möller UA, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2019;127:S1-S7.
2. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diab Endocrinol. 2017;5(6):431-437.
3. Ray KK, Seshasai SR, Wjesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772.
4. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158.
5. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diab Endocrinol. 2021;9(10):653-662.
6. Simó-Servat O, Hernández C, Simó R. Diabetic retinopathy in the context of patients with diabetes. Ophthal Res. 2019;62(4):211-217.
7. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):2-9.
8. Hammes H-P. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61(1):29-38.
9. Huang H, He J, Johnson DK, et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition. Diabetes. 2015;64(1):200-212.
10. Delaney P, Jager KJ, Bökemamp A, et al. CKD: a call for an age-adapted definition. J Am Soc Nephrol. 2019;30(10):1785–1805.
11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045.
12. Dietrich I, Braga GA, de Melo FG, da Costa Silva Silva ACC. The diabetic foot as a proxy for cardiovascular events and mortality review. Curr Atheroscler Rep. 2017;19(11):1-5.

13. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.

14. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampopoulo K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):110-116.

15. Buitrago-Lopez A, van den Hooven EH, Rueda-Clausen CF, et al. Socioeconomic status is positively associated with measures of adiposity and insulin resistance, but inversely associated with dyslipidaemia in Colombian children. J Epidemiol Commun Health. 2015;69(6):580-587.

16. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123.

17. Lai S. Chronic kidney disease and diabetes—a potential causal link. EBioMedicine. 2016;6:10-11.

18. Lee MMY, Petrie MC, McMurray JJV, Sattar N. How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like Peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and ongoing mechanistic trials. Arterioscler Thromb Vasc Biol. 2020;40(3):506-522.

19. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-R98.

20. Burgess S, Butterworth AS, Thompson JR. Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors. J Clin Epidemiol. 2016;69:208-216.

21. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. Welcome Open Res. 2019;4:186.

22. Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

23. Vincent EE, Yaghoobkar H. Using genetics to decipher the link between type 2 diabetes and cancer: shared aetiology or downstream consequence? Diabetologia. 2020;63(9):1706-1717.

24. Evans DM, Davey SG. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet. 2015;16:327-350.

25. Sekula P, Del Greco MF, Pattaro C, Kötten A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253-3265.

26. Huang M, Laina-Nicaise LD, Zha L, Tang G, Cheng X. Causal Association of Type 2 diabetes mellitus and glycemic traits with cardiovascular diseases and lipid traits: a Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13:840579.

27. Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. Neurology. 2017;89(5):454-460.

28. Liu J, Rutten-Jacobs L, Liu M, Markus HS, Traylor M. Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: a Mendelian randomization analysis. Stroke. 2018;49(6):1325-1331.

29. Harati H, Zanetti D, Rao A, et al. No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Diabetologia. 2019;62(5):800-804.

30. Udler MS, Kim J, von Grothuss M, et al.; Christopher D. Anderson on behalf of METASTROKE and the ISGC. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med 2018;15(9):e1002654.

31. Udler MS. Type 2 diabetes: multiple genes, multiple diseases. Curr Diab Rep. 2019;19(9):55.

32. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diab Endocrinol. 2018;6(5):361-369.

33. Lugner M, Gudbjörnsdottir S, Sattar N, et al. Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. Diabetologia. 2021;64(9):1973-1981.

34. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersay AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diab Endocrinol. 2019;7(6):442-451.

35. Yang H, Sloan G, Ye Y, et al. New perspective in diabetic nephropathy: from the periphery to the brain, a call for early detection, and precision medicine. Front. Endocrinol. 2020;10:1-2.

36. Mutie PM, Pomares-Millard H, Atabaki-Pasdar N, et al. An investigation of causal relationships between prediabetes and vascular complications. Nat. Commun. 2020;11(1):4592.

37. Liu B, Mason AM, Sun L, Di Angelantonio E, Gill D, Burgess S. Genetically predicted type 2 diabetes mellitus liability, glycated hemoglobin and cardiovascular diseases: a wide-angled Mendelian randomization study. Genes. 2021;12(10):1644.

38. Emanuelsson F, Marott S, Tybjærg-Hansen A, Nordestgaard BG, Benn M. Impact of glucose level on micro- and macrovascular disease in the general population: a Mendelian randomization study. Diabetes Care. 2020;43(4):894-902.

39. Chen W, Wang S, Lv W, Pan Y. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001217.

40. Collaborators GO. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27.

41. Sun J, Zhou W, Gu T, Zhu D, Bi Y. A retrospective study on association between obesity and cardiovascular risk diseases with aging in Chinese adults. Sci Rep. 2018;8(1):5806.

42. Lu J, Liu X, Jiang S, et al. Body mass index and risk of diabetic nephropathy: a Mendelian randomization study. J Clin Endocrinol Metab. 2022;107(6):1599-1608.

43. Geng T, Smith CE, Li C, Huang T. Childhood BMI and adult type 2 diabetes, coronary artery diseases, chronic kidney disease, and cardiometabolic traits: a Mendelian randomization analysis. Diabetes Care. 2018;41(5):1089-1096.

44. Chan JCY, Chee ML, Tan NYQ, Cheng CY, Wong TY, Sabanayagam C. Differential effect of body mass index on the incidence of diabetes and diabetic retinopathy in two Asian populations. Nutr Diabetes. 2018;8(1):16.

45. He C, Zhang M, Li J, et al. Novel insights into the consequences of obesity: a phenotype-wide Mendelian randomization study. Eur J Hum Genet. 2022;30:540-546.

46. Dobrca E, Gaman MA, Cozma MA, Gaman AM, Diaconu CC. Macrovascular and microvascular complications In type 2 diabetes mellitus. J Hypertens. 2019;37:e140-e141.
47. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular Disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575-584.

48. Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res. 2017;40(9):795-806.

49. Sun D, Zhou T, Heianza Y, et al. Type 2 diabetes and hypertension. Circ Res. 2019;124(6):930-937.

50. Wan EYF, Fung WT, Schooling CM, et al. Blood pressure and risk of cardiovascular disease in UK biobank: a mendelian randomization study. Hypertension. 2021;77(2):367-375.

51. Zheng J, Zhang Y, Rasheed H, et al. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int J Epidemiol. 2022;50(6):1995-2010.

52. Xiu X, Zhang H, Xue A, et al. Genetic evidence for a causal relationship between type 2 diabetes and peripheral artery disease in both Europeans and east Asians. BMC Med. 2022;20(1):300.

53. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551.

54. Lingvay I, Sumithran P, Cohen RV, Le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394-405.

55. Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2022;2022:1-42.

How to cite this article: Ahmed A, Sattar N, Yaghoobkar H. Advancing a causal role of type 2 diabetes and its components in developing macro- and microvascular complications via genetic studies. Diabet Med. 2022;39:e14982. doi: 10.1111/dme.14982